Teaching an old dog new tricks: next-generation CAR T cells (Q58561607)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

2 references

1 August 2020

23 August 2022

Teaching an old dog new tricks: next-generation CAR T cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

1 August 2020

adoptive immunotherapy

1 reference

1 August 2020

3

Stefan Endres

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

Nicholas Tokarew

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Justyna Ogonek

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Michael von Bergwelt-Baildon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Sebastian Kobold

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

language of work or name

English

0 references

publication date

9 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

2 May 2020

1 January 2019

2 references

1 August 2020

23 August 2022

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 August 2020

23 August 2022

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

26-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

2 May 2020

copyright license

1 reference

Creative Commons Attribution

1 August 2020

1 reference

23 August 2022

Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

How Do Cytotoxic Lymphocytes Kill Cancer Cells?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chimeric antigen receptor T-cell therapies for lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Difference between hematological malignancy and solid tumor research articles published in four major medical journals

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CAR-T cells: the long and winding road to solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The Principles of Engineering Immune Cells to Treat Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The urgent need to recover MHC class I in cancers for effective immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Engineering CAR-T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

T-cell antigen receptor signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CD28-mediated co-stimulation: a quantitative support for TCR signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CAR T cells for solid tumors: armed and ready to go?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Converting Cold into Hot Tumors by Combining Immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Migrating into the Tumor: a Roadmap for T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Immune oncology, immune responsiveness and the theory of everything.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A quantum leap in cancer vaccines?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Allogeneic and autologous melanoma vaccines: where have we been and where are we going?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Current status of immunological therapies for prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

1 reference

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Improving homing in T cell therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Distinct roles of helper T-cell subsets in a systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The composition of T-cell subsets are altered in the burn wound early after injury

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Fine-tuning Tumor Immunity with Integrin Trans-regulation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Reassessing target antigens for adoptive T-cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The integrin αvβ6: a novel target for CAR T-cell immunotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A compound chimeric antigen receptor strategy for targeting multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Inducible apoptosis as a safety switch for adoptive cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

T cell transduction and suicide with an enhanced mutant thymidine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

An inducible caspase 9 safety switch for T-cell therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

There Will Be Blood Tests

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Redirecting gene-modified T cells toward various cancer types using tagged antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Adoptive immunotherapy for cancer: building on success

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A versatile system for rapid multiplex genome-edited CAR T cell generation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Reversal of tumor immune inhibition using a chimeric cytokine receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

IL-2: the first effective immunotherapy for human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Endotoxin-induced serum factor that stimulates gamma interferon production

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0325-1

7 January 2021

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

https://pubmed.ncbi.nlm.nih.gov/30413825

1 reference

12 December 2020

Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

Immunotherapy in Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

Unraveling Antibody Display: Systems Biology and Personalized Medicine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/30413825

12 December 2020

10.1038/S41416-018-0325-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30413825%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

PubMed publication ID

30413825

1 reference